Lucid Diagnostics INC DEF 14A proxy statements

Lucid Diagnostics Inc. has filed its proxy statement for the 2026 Annual Meeting, seeking approval for a capital increase and director elections.

Lucid Diagnostics Inc. has filed a definitive proxy statement with the SEC.

Lucid Diagnostics Inc. will hold its annual meeting on June 18, 2025, to vote on director elections, approve a stock issuance related to convertible notes, and ratify the appointment of its accounting firm.

Lucid Diagnostics has rescheduled its annual meeting to July 23, 2024, to modify proposals including stock issuance approval and an increase in authorized common stock.

Lucid Diagnostics Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Lucid Diagnostics Inc. has rescheduled its 2024 annual meeting of stockholders from June 20, 2024, to July 23, 2024, to modify the proposals to be voted upon.

Lucid Diagnostics Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Lucid Diagnostics Inc. will hold its annual stockholders meeting virtually on June 20, 2024, to vote on director elections, stock issuance approval, and accountant ratification.